Vaxdyn awarded €14.5 Million from the EIC Accelerator to Fund the Clinical Phase of Its Vaccine Platform
- The European Commission is committed to combating antibiotic resistance through vaccines, selecting Vaxdyn's competitive project.
- The entry into clinical phase of K-Vax, the vaccine against Klebsiella pneumoniae, was among the 68 projects awarded at the European level.
Thanks to the support of the international accelerator CARB-X and private investors, Vaxdyn, based in Seville, has successfully built a preclinical package that has validated its unique vaccine technology against the main antibiotic-resistant bacteria. To finance the clinical validation, Vaxdyn competed with 969 European tech companies from all sectors in the final phase of the latest call of the European Commission's EIC Accelerator program.
The project was awarded €2.5 million in grants for the first clinical phase in healthy volunteers and an additional €12 million through the acquisition of company shares by the Commission to finance Phase 2 of efficacy testing in the adult population at risk of infections by Klebsiella pneumoniae.
In statements by Vaxdyn's CEO, Juanjo Infante, "securing funding from the EIC Accelerator is a tremendous achievement that demonstrates the great work done over the years to build a globally relevant project and validates the strategy of preventing diseases caused by antibiotic-resistant bacteria by strengthening the immunity of at-risk populations."
The company has a plan to meet the demand for vaccines to stop the spread of Klebsiella pneumoniae in the adult hospital population and in newborns, where Klebsiella is already the leading cause of neonatal sepsis worldwide. The entry into the clinical phase also involves the closure of an ongoing Series A funding round.